Answers are grounded in this paper and cite their sources.
Reveals distinct immune microenvironment subtypes impact immunotherapy effectiveness in glioblastoma, suggesting tailored approaches are needed.
GBM comprise three functional TIME subtypes with divergent vascular-immune landscapes that require subtype-specific therapeutic strategies. TIME-med tumors are most amenable to immunotherapies. TIME-low tumors derive transient effects with anti-angiogenic immunomodulating therapies, and TIME-high are resistant or even experience worse outcome without targeted reversal of myeloid immunosuppression.
No takes yet. Share an insight, caveat, or question.
Weng et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: